90,788 Shares in Becton, Dickinson and Company $BDX Acquired by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 90,788 shares of the medical instruments supplier’s stock, valued at approximately $13,739,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bryn Mawr Trust Advisors LLC purchased a new position in Becton, Dickinson and Company during the second quarter valued at $7,011,000. Mill Capital Management LLC purchased a new stake in Becton, Dickinson and Company in the 2nd quarter worth $522,000. Northstar Group Inc. bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $240,000. Northside Capital Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 18.3% during the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock valued at $9,280,000 after purchasing an additional 9,494 shares during the last quarter. Finally, Cardinal Capital Management Inc. grew its position in shares of Becton, Dickinson and Company by 6.6% during the second quarter. Cardinal Capital Management Inc. now owns 178,421 shares of the medical instruments supplier’s stock valued at $27,000,000 after purchasing an additional 11,039 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 11,779 shares of company stock worth $1,974,669. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Up 0.7%

Shares of NYSE BDX opened at $183.16 on Friday. The firm’s 50-day moving average price is $157.84 and its 200-day moving average price is $161.70. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $50.47 billion, a price-to-earnings ratio of 55.17, a P/E/G ratio of 12.82 and a beta of 0.19. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the firm earned $3.68 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BDX shares. Barclays boosted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. TD Cowen raised their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Piper Sandler lifted their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Finally, UBS Group began coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.